These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7972625)

  • 1. Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. A pharmaceutical industry perspective on drug labeling.
    Robinson DS
    Psychopharmacol Bull; 1994; 30(1):23-5. PubMed ID: 7972625
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 3. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 4. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 5. An update on the therapeutic orphan.
    Wilson JT
    Pediatrics; 1999 Sep; 104(3 Pt 2):585-90. PubMed ID: 10469794
    [No Abstract]   [Full Text] [Related]  

  • 6. An overview of current programs on drug development and regulation for small ruminants--pharmaceutical industry perspective.
    Terry M
    Vet Hum Toxicol; 1993; 35 Suppl 2():12-3. PubMed ID: 8236759
    [No Abstract]   [Full Text] [Related]  

  • 7. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 9. Extra-label drug use--pharmaceutical industry view.
    Welser JR
    J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571
    [No Abstract]   [Full Text] [Related]  

  • 10. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule.
    Connor JD
    Pediatrics; 1999 Sep; 104(3 Pt 2):610-3. PubMed ID: 10469801
    [No Abstract]   [Full Text] [Related]  

  • 11. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 13. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 14. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlicensed and off-label drug use in children.
    Bavdekar SB; Gogtay NJ
    J Postgrad Med; 2005; 51(4):249-52. PubMed ID: 16388164
    [No Abstract]   [Full Text] [Related]  

  • 16. Happier, hornier, hairier.
    Nat Biotechnol; 2003 Jan; 21(1):1. PubMed ID: 12511892
    [No Abstract]   [Full Text] [Related]  

  • 17. Government investigations in the pharmaceutical industry: off-label promotion, fraud and abuse, and false claims.
    Kalb PE; Bass IS
    Food Drug Law J; 1998; 53(1):63-70. PubMed ID: 11795337
    [No Abstract]   [Full Text] [Related]  

  • 18. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 19. Proposed US Food and Drug Administration guidance for industry on distributing medical publications about the risks of prescription drugs and biological products: a misguided approach.
    Wolfe SM
    JAMA Intern Med; 2014 Oct; 174(10):1543-4. PubMed ID: 25127222
    [No Abstract]   [Full Text] [Related]  

  • 20. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.